SPECIALIZED Therapeutics
yesterday announced a license
agreement which will see
Munidpharma assume all
commercialisation responsibilities
for anti-emetic products Aloxi
(palonosetron hydrochloride) and
Akynzeo (netupitant/palonosetron)
in the Australian & NZ markets.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Mar 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Mar 16
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.